PT-141 (Bremelanotide): Melanocortin System Research & Clinical Data

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is PT-141?

PT-141, also known by its pharmaceutical name bremelanotide, is a synthetic cyclic heptapeptide derived from the melanocortin peptide Melanotan II. It acts as a non-selective agonist at melanocortin receptors, with particular affinity for the melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptor subtypes. Unlike earlier compounds in the melanocortin family that were developed for tanning or appetite research, PT-141 was specifically investigated for its effects on sexual function mediated through central nervous system melanocortin pathways.

The discovery of PT-141’s primary research application arose serendipitously during clinical trials of Melanotan II. Researchers observed that subjects receiving Melanotan II reported significant effects on sexual arousal and function — effects that appeared to be mediated centrally (in the brain) rather than through peripheral vascular mechanisms. This observation led to the development of PT-141 as a structurally optimized derivative with a more targeted pharmacological profile.

In 2019, bremelanotide was approved by the FDA under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first melanocortin receptor agonist approved for this indication. This approval was based on two phase III clinical trials (RECONNECT studies) involving over 1,200 participants.

The Melanocortin System

Understanding PT-141 requires familiarity with the melanocortin system — one of the most ancient and conserved peptide signaling systems in vertebrate biology. The system consists of five receptor subtypes (MC1R through MC5R), endogenous agonist peptides (α-MSH, β-MSH, γ-MSH, and ACTH), and an endogenous antagonist (agouti-related peptide, AgRP).

Receptor	Primary Location	Key Functions
MC1R	Melanocytes, immune cells	Pigmentation, inflammation
MC2R	Adrenal cortex	Cortisol production (ACTH receptor)
MC3R	Brain (hypothalamus), gut	Energy homeostasis, sexual function
MC4R	Brain (hypothalamus, cortex)	Appetite regulation, sexual function, energy balance
MC5R	Exocrine glands, skin	Sebaceous gland function

PT-141’s primary research relevance involves MC3R and MC4R, which are densely expressed in brain regions associated with sexual behavior, arousal, and motivation — including the hypothalamus, limbic system, and medial preoptic area.

How PT-141 Works: Mechanism of Action

PT-141’s mechanism of action is fundamentally different from phosphodiesterase-5 (PDE5) inhibitors (such as sildenafil), which act on peripheral vascular smooth muscle. PT-141 acts centrally, modulating sexual arousal through brain-based melanocortin pathways:

• MC4R activation in the hypothalamus — PT-141 binds to MC4R in the paraventricular nucleus (PVN) and medial preoptic area (MPOA) of the hypothalamus, regions that integrate hormonal, sensory, and emotional inputs to regulate sexual motivation and arousal. MC4R activation in these regions triggers downstream signaling that includes oxytocin release and modulation of dopaminergic pathways.
• MC3R activation — MC3R is expressed in overlapping brain regions and appears to play a modulatory role in sexual behavior. While MC4R is considered the primary mediator of PT-141’s sexual function effects, MC3R activation may contribute to the overall response, particularly in energy sensing and motivational aspects.
• Oxytocin pathway engagement — MC4R activation in the PVN stimulates oxytocin release, which is transmitted to brain regions involved in sexual arousal and pair bonding. This oxytocinergic component has been demonstrated in rodent studies and is considered a key mediator of PT-141’s central effects.
• Dopaminergic modulation — Research has documented that melanocortin receptor activation in the hypothalamus influences dopamine release in the mesolimbic reward pathway. This mechanism may contribute to the motivational and desire-related aspects of PT-141’s observed effects, as opposed to purely reflexive arousal responses.
• NO/cGMP pathway (secondary) — While PT-141’s primary mechanism is central, downstream signaling through the hypothalamic-spinal pathway ultimately involves nitric oxide (NO) and cyclic GMP (cGMP) at the peripheral tissue level. However, this peripheral component is activated through central neural circuits rather than direct local action, distinguishing PT-141 from PDE5 inhibitors.

Clinical Trial Data

RECONNECT Trials (Phase III — HSDD in Women)

The two pivotal RECONNECT studies enrolled 1,247 premenopausal women diagnosed with HSDD and randomized them to PT-141 (1.75 mg subcutaneous) or placebo, used as needed before anticipated sexual activity. Key findings:

• Primary endpoint (desire) — PT-141 produced statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain score compared to placebo. The mean improvement was modest but consistent across both trials.
• Secondary endpoint (distress) — Significant reductions in the Female Sexual Distress Scale — Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score, indicating reduced distress associated with low desire.
• Onset — Effects on desire and arousal were observed beginning approximately 30–60 minutes after subcutaneous injection.
• Responder analysis — Approximately 25% of PT-141-treated participants were categorized as responders (clinically meaningful improvement in both desire and distress measures), compared to approximately 17% for placebo.

Male Sexual Function Studies

Earlier clinical studies (phase II) investigated PT-141 in men with erectile dysfunction. A 2005 study published in the Journal of Urology evaluated intranasal PT-141 in men with ED and reported:

• Dose-dependent improvements in erectile response, as measured by rigidity monitoring
• Positive effects in a subset of patients who had not responded to sildenafil, suggesting a complementary mechanism
• Onset of effect within 30 minutes of intranasal administration

A notable finding was that PT-141 appeared to affect erectile function through arousal-mediated pathways — patients reported increased subjective desire in addition to physiological response, which is not typically observed with PDE5 inhibitors. However, the intranasal delivery program was ultimately discontinued in favor of the subcutaneous route.

Pharmacokinetic Data

Clinical pharmacokinetic studies have characterized PT-141’s profile after subcutaneous administration:

• Tmax — Peak plasma concentrations reached approximately 1 hour post-injection
• Half-life — Approximately 2.7 hours
• Bioavailability — Approximately 100% via subcutaneous route
• Metabolism — Hydrolyzed to multiple metabolites; primary elimination is renal
• Duration of effect — Clinical effects observed for up to 24 hours in some subjects, despite the relatively short plasma half-life, suggesting sustained central receptor engagement

Relationship to Melanotan I and Melanotan II

PT-141 exists within a family of synthetic melanocortin peptides that includes Melanotan I and Melanotan II. Understanding the relationships and differences between these compounds is important for research context:

• Melanotan I (afamelanotide) — A linear α-MSH analog with selectivity for MC1R. Primarily investigated for pigmentation and photoprotection. FDA-approved as Scenesse for erythropoietic protoporphyria. Minimal sexual function effects due to MC1R selectivity.
• Melanotan II — A cyclic α-MSH analog that is non-selective across melanocortin receptors. Produces both pigmentation (MC1R) and sexual function effects (MC3R/MC4R). PT-141 was derived from Melanotan II through structural modification to reduce MC1R activity while retaining MC3R/MC4R activity.
• PT-141 (bremelanotide) — Structurally similar to Melanotan II but with reduced pigmentation effects. The primary research and clinical focus is on MC3R/MC4R-mediated central sexual function rather than MC1R-mediated tanning.

Beyond Sexual Function: Emerging Research Areas

Hemorrhagic Shock Research

An unexpected but significant area of PT-141 research involves its effects in animal models of hemorrhagic shock. Studies have demonstrated that melanocortin agonists, including PT-141, can reduce mortality and organ damage in rodent hemorrhage models. This effect appears to be mediated through MC3R activation and involves modulation of the inflammatory response to severe blood loss.

Inflammation and Immune Modulation

The broader melanocortin system has well-documented anti-inflammatory properties, and PT-141’s activation of MC3R and MC4R positions it within this anti-inflammatory network. Research has investigated melanocortin agonists in models of inflammatory bowel disease, arthritis, and neuroinflammation, though most of this work has used α-MSH or other analogs rather than PT-141 specifically.

Energy Balance and Metabolic Research

MC4R is a key regulator of appetite and energy homeostasis — loss-of-function MC4R mutations are the most common monogenic cause of obesity in humans. While PT-141 was developed for sexual function rather than metabolic applications, its MC4R agonist activity has generated ancillary research interest in metabolic contexts. Clinical studies have documented transient appetite suppression and nausea as side effects of PT-141, consistent with MC4R-mediated anorexigenic signaling.

Dosing in Research and Clinical Studies

Study Context	Dose	Route	Frequency
RECONNECT trials (women)	1.75 mg	Subcutaneous	As needed (max 1×/day, ≤8×/month)
Phase II (men, intranasal)	7–20 mg	Intranasal	As needed
Phase II (men, subcutaneous)	0.3–10 mg	Subcutaneous	As needed
Hemorrhagic shock (animal)	160–480 μg/kg	IV bolus	Single dose post-hemorrhage

Reconstitution and Handling

PT-141 is typically supplied as a lyophilized powder for research applications:

• Storage — Lyophilized PT-141 at -20°C for long-term stability; protect from light
• Reconstitution — Reconstitute with sterile bacteriostatic water. Add solvent slowly along the vial wall.
• Stability — Reconstituted solution stable for approximately 14–20 days at 2–8°C
• Cyclic peptide advantage — PT-141’s cyclic structure confers greater proteolytic resistance than linear peptides, contributing to its relatively good stability profile

Safety Profile

The RECONNECT trials and other clinical studies provide substantial human safety data for PT-141. The most commonly reported adverse effects include:

• Nausea — The most frequent side effect, reported by approximately 40% of subjects in clinical trials. Typically mild to moderate and self-limiting, resolving within hours. This is consistent with MC4R-mediated signaling in brain regions that influence nausea.
• Flushing — Reported by approximately 20% of subjects, consistent with melanocortin-mediated vascular effects.
• Injection site reactions — Mild erythema or discomfort at the subcutaneous injection site.
• Headache — Reported by approximately 11% of subjects.
• Blood pressure — Transient increases in systolic blood pressure (mean ~3 mmHg) were observed in clinical trials. The FDA labeling includes a precaution regarding use in patients with cardiovascular disease or uncontrolled hypertension.
• Hyperpigmentation — Focal skin darkening, particularly on the face and gingiva, was reported in some subjects with repeated use, consistent with residual MC1R activity.

Regulatory Status

PT-141 (bremelanotide) has a unique regulatory position as one of the few melanocortin peptides to achieve FDA approval:

• FDA-approved (2019) — As Vyleesi (bremelanotide injection, 1.75 mg) for HSDD in premenopausal women
• Not approved for male sexual dysfunction, tanning, or any other indication
• Schedule status — Not a controlled substance, but available only by prescription in the approved formulation
• Research use — Available from research suppliers as a lyophilized peptide for laboratory investigation

Current Limitations and Future Directions

• Nausea limits broader adoption — The 40% nausea rate in clinical trials represents a significant tolerability barrier that future formulation research may address
• Modest effect sizes in HSDD — While statistically significant, the clinical effect sizes in the RECONNECT trials were modest, raising questions about patient selection and responder identification
• Male indication not approved — Despite positive phase II data, PT-141 development for male sexual dysfunction has not advanced to pivotal trials
• Central mechanism complexity — The multi-receptor, multi-pathway nature of PT-141’s central action makes precise mechanistic dissection challenging
• Long-term exposure data — Extended-use safety data (beyond 12 months) is limited

Future research directions include the development of more selective MC4R agonists with reduced nausea profiles, investigation of oral or transmucosal delivery formulations, expanded research in hemorrhagic shock and inflammatory conditions, and identification of biomarkers that predict treatment response.

Summary

PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on MC3R and MC4R in the central nervous system to modulate sexual arousal and desire through brain-based pathways. It is the first and only melanocortin peptide approved for a sexual function indication, based on phase III clinical trial data demonstrating efficacy in premenopausal women with HSDD. Its central mechanism of action — mediated through hypothalamic melanocortin receptors, oxytocin pathways, and dopaminergic signaling — distinguishes it fundamentally from peripheral vascular agents. Emerging research extends beyond sexual function into hemorrhagic shock, inflammation, and metabolic regulation.

View PT-141 in our research catalog. Related melanocortin peptides: Melanotan I and Melanotan II.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Kingsberg et al.	2019	Phase 3 RCT	Bremelanotide for HSDD — two RECONNECT registration trials	PMC6819021
Simon et al.	2022	Review	Bremelanotide for treatment of female hypoactive sexual desire	PMC8788464
Kingsberg et al.	2019	Phase 3 Extension	Long-term safety and efficacy of bremelanotide for HSDD	PMC6819023
Hadley	2005	Review	Melanocortin receptors, melanotropic peptides, and penile erection	PMC2694735
Pfaus et al.	2017	Review	Bremelanotide for female sexual dysfunctions in premenopausal women	PMC5384512
Burrello et al.	2017	Clinical Study	Ambulatory blood pressure monitoring with melanocortin receptor agonist	PMC5338879
Rosen et al.	2004	Phase 2 RCT	Subcutaneous PT-141 safety and pharmacodynamics in ED patients	PMID 14999221
Diamond et al.	2006	Phase 2 RCT	Effect on subjective sexual response in premenopausal women	PMID 16839319

This article is for informational and research purposes only. It does not constitute medical advice. All peptides sold by NorthPeptide are intended exclusively for laboratory and research use. Not for human consumption.